Share price pullbacks for Eledon Pharmaceuticals are frequently driven by broader market shifts affecting clinical-stage biotechnology equities, periodic capital-raising activities that dilute existing shares, or typical investor caution ahead of major trial readouts. Because pre-revenue biotech companies rely heavily on external funding and milestone achievements, short-term negative macro sentiment or delays in clinical timelines can trigger temporary downward pressures on the stock.